- Home
- / HanAll BioPharma
HanAll BioPharma
Stock Price
₩45.7 K
2024-10-29
Market Capitalization
₩2.3 T
2024-10-29
Revenue
₩155.2 B
FY, 2025
HanAll BioPharma Summary
Company Summary
- Overview
- HanAll BioPharma (한올바이오파마) is a pharmaceutical company. It offers specialty drugs and over-the-counter products for the treatment of various severe autoimmune diseases, cerebrovascular and peripheral blood vessel disorder, hypertension, atherosclerotic symptom, acute coronary syndrome, etc.
- Type
- Public
- Status
- Active
- Founded
- 1973
- HQ
- Seoul, KR | view all locations
- Website
- http://en.hanall.co.kr/
- Cybersecurity rating
- ESG rating
Table of Contents
LocationsView all
4 locations detected
Seoul, Seoul HQ
Korea (Republic of)
Daewoong Building 3F, 12 Bongeunsa-ro 114-gil
Daejeon, Daejeon
Korea (Republic of)
#208, 2F, Megan Techno World, 199, Techno 2-ro
Daejeon, Daejeon
Korea (Republic of)
43 Sangseodang 1-gil
Suwon, Gyeonggi-do
Korea (Republic of)
10th floor, Gyeonggi Bio Center, 147
HanAll BioPharma Financials
Summary Financials
- Revenue (FY, 2025)
- ₩155.2B
- Gross profit (FY, 2025)
- ₩83.9B
- Net income (FY, 2025)
- (₩5.6B)
- Cash (FY, 2025)
- ₩24.7B
- EBIT (FY, 2025)
- (₩2.1B)
- Enterprise value
- $2.3T
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026